metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
KRAS gene alteration defined cancer KRAS gene alteration defined cancer
versus no control (uncontrolled study)
	sotorasib
	CodeBreaK 100, 2021 N Engl J Med 2021 Jun 24;384(25):2371-2381. NCT03600883	DESC	KRAS gene alteration defined cancer, metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)	otorasib, administered orally at a dose of 960 mg once daily		patients with KRAS p.G12C-mutated advanced NSCLC previously treated with standard therapies	124	NA	no results	no results
NTRK gene alteration NTRK gene alteration
versus no control (uncontrolled study)
	larotrectinib
	Drilon (basket), 2018 Lancet Oncol 2020 Apr;21(4):531-540. N Engl J Med 2018 Feb 22;378(8):731-739. NCT02576431	DESC	lung cancer : non small cell (NSCLC), NTRK gene alteration	larotrectinib		TRK Fusion-Positive Cancers in Adults and Children	-/-	NA	no results	no results
RET gene alteration defined cancer RET gene alteration defined cancer
versus no control (uncontrolled study)
	pralsetinib
	ARROW unpublished Lancet Oncol 2021 Jul;22(7):959-969. NCT03037385	DESC	lung cancer : non small cell (NSCLC), RET gene alteration defined cancer	pralsetinib		adult patients with metastatic RET fusion-positive non-small cell lung cancer	114	NA	no results	no results
	selpercatinib
	LIBRETTO-001 trial (lung cancer) unpublished N Engl J Med 2020 Aug 27;383(9):813-824. NCT03157128	DESC	lung cancer : non small cell (NSCLC), RET gene alteration defined cancer	selpercatinib		patients with locally advanced or metastatic RET fusion-positive NSCLC	-/-	NA	no results	no results